Which has higher valuation and earnings, STAB or CMRA?

Statera Biopharma has higher earnings, but lower revenue than Comera Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Statera Biopharma N/A N/A N/A N/A N/A Comera Life Sciences $1.00M 0.00 -$18M -$0.31 N/A

Is STAB or CMRA more profitable?

Company Net Margins Return on Equity Return on Assets Statera Biopharma N/A N/A N/A Comera Life Sciences N/A N/A N/A

Which has preferable earnings and valuation, EFTR or STAB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eFFECTOR Therapeutics N/A N/A -$35.81M -$13.08 N/A Statera Biopharma N/A N/A N/A N/A N/A

Is EFTR or STAB more profitable?

Company Net Margins Return on Equity Return on Assets eFFECTOR Therapeutics N/A N/A N/A Statera Biopharma N/A N/A N/A

Which has better valuation and earnings, STAB or SYRS?

Statera Biopharma has higher earnings, but lower revenue than Syros Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Statera Biopharma N/A N/A N/A N/A N/A Syros Pharmaceuticals $386K 0.01 -$164.57M -$3.03 N/A

Is STAB or SYRS more profitable?

Statera Biopharma's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Statera Biopharma N/A N/A N/A Syros Pharmaceuticals N/A -3,369.56% -97.04%

Do analysts recommend ADTX or STAB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Statera Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, ADTX or STAB?

Statera Biopharma has lower revenue, but higher earnings than Aditxt. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.29 -$41.71M -$100.79 thousand N/A Statera Biopharma N/A N/A N/A N/A N/A

Which has better earnings & valuation, CALA or STAB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Calithera Biosciences N/A N/A -$39.65M N/A N/A Statera Biopharma N/A N/A N/A N/A N/A

Is CALA or STAB more profitable?

Company Net Margins Return on Equity Return on Assets Calithera Biosciences N/A N/A N/A Statera Biopharma N/A N/A N/A

Statera Biopharma (STAB) Competitors

$0.0001 0.00 (0.00%)

As of 07/2/2026 02:00 PM Eastern

Compare

STAB vs. CMRA, EFTR, SYRS, ADTX, and CALA

Should you buy Statera Biopharma stock or one of its competitors? MarketBeat compares Statera Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Statera Biopharma include Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), Syros Pharmaceuticals (SYRS), Aditxt (ADTX), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry.

How does Statera Biopharma compare to Comera Life Sciences?

Statera Biopharma (NASDAQ:STAB) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Statera Biopharma has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Statera Biopharma has higher earnings, but lower revenue than Comera Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Statera Biopharma	N/A	N/A	N/A	N/A	N/A
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.31	N/A

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company	Overall Sentiment
Statera Biopharma	Neutral
Comera Life Sciences	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Statera Biopharma	N/A	N/A	N/A
Comera Life Sciences	N/A	N/A	N/A

Summary

Comera Life Sciences beats Statera Biopharma on 3 of the 3 factors compared between the two stocks.

How does Statera Biopharma compare to eFFECTOR Therapeutics?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Company	Net Margins	Return on Equity	Return on Assets
eFFECTOR Therapeutics	N/A	N/A	N/A
Statera Biopharma	N/A	N/A	N/A

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Statera Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eFFECTOR Therapeutics	N/A	N/A	-$35.81M	-$13.08	N/A
Statera Biopharma	N/A	N/A	N/A	N/A	N/A

eFFECTOR Therapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company	Overall Sentiment
eFFECTOR Therapeutics	Neutral
Statera Biopharma	Neutral

Summary

eFFECTOR Therapeutics beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.

How does Statera Biopharma compare to Syros Pharmaceuticals?

Statera Biopharma (NASDAQ:STAB) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Statera Biopharma has higher earnings, but lower revenue than Syros Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Statera Biopharma	N/A	N/A	N/A	N/A	N/A
Syros Pharmaceuticals	$386K	0.01	-$164.57M	-$3.03	N/A

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Statera Biopharma	Neutral
Syros Pharmaceuticals	Neutral

Statera Biopharma has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

Statera Biopharma's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Statera Biopharma	N/A	N/A	N/A
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

91.5% of Syros Pharmaceuticals shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Syros Pharmaceuticals beats Statera Biopharma on 5 of the 7 factors compared between the two stocks.

How does Statera Biopharma compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Statera Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aditxt's average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Aditxt	Neutral
Statera Biopharma	Neutral

15.5% of Aditxt shares are held by institutional investors. 0.0% of Aditxt shares are held by company insiders. Comparatively, 5.5% of Statera Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Statera Biopharma has lower revenue, but higher earnings than Aditxt.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.29	-$41.71M	-$100.79 thousand	N/A
Statera Biopharma	N/A	N/A	N/A	N/A	N/A

Statera Biopharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Statera Biopharma's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Statera Biopharma	N/A	N/A	N/A

Aditxt has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market.

Summary

Aditxt beats Statera Biopharma on 5 of the 9 factors compared between the two stocks.

How does Statera Biopharma compare to Calithera Biosciences?

Calithera Biosciences (NASDAQ:CALA) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Calithera Biosciences	N/A	N/A	N/A
Statera Biopharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A
Statera Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Calithera Biosciences	Neutral
Statera Biopharma	Neutral

Calithera Biosciences has a beta of -1.36, suggesting that its stock price is 236% less volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market.

Summary

Calithera Biosciences and Statera Biopharma tied by winning 1 of the 2 factors compared between the two stocks.

Get Statera Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STAB vs. The Competition

Export

Metric	Statera Biopharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1K	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	0.00	1.66	28.02	24.70
Price / Sales	N/A	127.11	540.37	99.49
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	N/A	8.17	10.96	6.46
Net Income	N/A	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	N/A	4.41%	5.25%	3.81%
1 Year Performance	N/A	49.43%	33.29%	23.90%

Statera Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STAB Statera Biopharma	N/A	$0.00 flat	N/A	+0.0%	$1K	N/A	N/A	20
CMRA Comera Life Sciences	N/A	N/A	N/A	N/A	$3K	$1.00M	N/A	2
EFTR eFFECTOR Therapeutics	N/A	$0.00 +200.0%	N/A	+200.0%	$3K	N/A	N/A	10
SYRS Syros Pharmaceuticals	N/A	$0.00 flat	N/A	-99.6%	$3K	$386K	N/A	120	High Trading Volume
ADTX Aditxt	0.6405 of 5 stars	$0.00 +19.0%	N/A	-100.0%	$2K	$14.34K	N/A	60	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STAB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Statera Biopharma (STAB) Competitors

STAB vs. CMRA, EFTR, SYRS, ADTX, and CALA

How does Statera Biopharma compare to Comera Life Sciences?

Summary

How does Statera Biopharma compare to eFFECTOR Therapeutics?

Summary

How does Statera Biopharma compare to Syros Pharmaceuticals?

Summary

How does Statera Biopharma compare to Aditxt?

Summary

How does Statera Biopharma compare to Calithera Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STAB vs. The Competition

Statera Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Statera Biopharma (STAB) Competitors

STAB vs. CMRA, EFTR, SYRS, ADTX, and CALA

How does Statera Biopharma compare to Comera Life Sciences?

Which has more risk and volatility, STAB or CMRA?

Which has higher valuation and earnings, STAB or CMRA?

Does the media refer more to STAB or CMRA?

Is STAB or CMRA more profitable?

Summary

How does Statera Biopharma compare to eFFECTOR Therapeutics?

Is EFTR or STAB more profitable?

Do institutionals & insiders have more ownership in EFTR or STAB?

Which has preferable earnings and valuation, EFTR or STAB?

Which has more volatility & risk, EFTR or STAB?

Does the media refer more to EFTR or STAB?

Summary

How does Statera Biopharma compare to Syros Pharmaceuticals?

Which has better valuation and earnings, STAB or SYRS?

Does the media favor STAB or SYRS?

Which has more volatility and risk, STAB or SYRS?

Is STAB or SYRS more profitable?

Do institutionals & insiders have more ownership in STAB or SYRS?

Summary

How does Statera Biopharma compare to Aditxt?

Do analysts recommend ADTX or STAB?

Does the media prefer ADTX or STAB?

Do insiders and institutionals hold more shares of ADTX or STAB?

Which has stronger earnings and valuation, ADTX or STAB?

Is ADTX or STAB more profitable?

Which has more risk & volatility, ADTX or STAB?

Summary

How does Statera Biopharma compare to Calithera Biosciences?

Is CALA or STAB more profitable?

Which has better earnings & valuation, CALA or STAB?

Does the media refer more to CALA or STAB?

Which has more risk and volatility, CALA or STAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STAB vs. The Competition

Statera Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools